Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the
extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular
uptake of adenosine via the equilibrative nucleoside transporter (ENT). This mechanism can
contribute to the beneficial effects and to the side effects (dyspnea) of ticagrelor in
patients with an acute myocardial infarction. In the current research proposal, we aim to
investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by
ENT inhibition.